21.5
Kardiyomiyopatinin yönetimi, altta yatan ya da tetikleyici nedenlerin ele alınmasını, kalp yetmezliğinin ilaçlarla tedavisini, beslenme değişiklikleri…
Kardiyomiyopatinin tıbbi yönetimi, düşük tuzlu bir diyet uygulamak, tolere edildiği gibi egzersiz yapmak ve daha fazla kardiyak hasarı önlemek için alkol ve tütünden kaçınmak gibi yaşam tarzı değişikliklerini içerir.
Tedaviler genellikle art yükü azaltmak için ACE inhibitörlerini, nörohormonal aktiviteyi kontrol etmek için beta-blokerleri ve aldosteron antagonistlerini ve ön yükü azaltmak ve semptomları hafifletmek için diüretikleri içerir.
Kan pıhtılaşması riski varsa antikoagülanlar kullanılır ve ritimler uygun antiaritmilerle tedavi edilir.
Ağır vakalar cerrahi müdahaleler gerektirir.
Örneğin, şiddetli hipertrofik kardiyomiyopati, kan akışını engelleyen kalınlaşmış septal duvarın bir kısmını çıkarmak için septal miyektomi gerektirebilir.
Alternatif olarak, açık kalp ameliyatı için uygun olmayanlar için uygun olan alkollü septal ablasyon, kontrollü enfarktüs ve septal incelmeyi indüklemek için bir koroner artere alkol enjekte etmeyi içerir.
Dilate kardiyomiyopati için, sekonder mitral yetersizliği ele almak için mitral kapak onarımı veya replasmanı önerilir.
Son olarak, dilate kardiyomiyopatiden kaynaklanan son dönem kalp yetmezliği ventriküler destek cihazı implantasyonu veya kardiyak transplantasyon gerektirebilir.
View the full transcript and gain access to JoVE Core videos
Q1: What lifestyle modifications help manage cardiomyopathy?
Cardiomyopathy management requires adopting a low-salt diet to reduce fluid retention and prevent further cardiac damage. Patients should follow a personalized exercise and rest plan to maintain fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent exacerbating symptoms and additional heart muscle damage.
Q2: Which medications are commonly used to treat cardiomyopathy?
Common pharmacological treatments include ACE inhibitors like lisinopril and beta-blockers like metoprolol to reduce afterload and control neurohormonal activity. Diuretics like furosemide reduce preload and alleviate symptoms, while aldosterone antagonists help manage heart failure. Anticoagulants prevent blood clots, and antiarrhythmics treat dysrhythmias when present.
Q3: What is septal myectomy and when is it used?
Septal myectomy is an open-heart surgical procedure for severe hypertrophic cardiomyopathy that removes a portion of the thickened septal wall obstructing blood flow. This surgery reduces symptoms and improves exercise capacity. It is the standard surgical intervention when medical management is ineffective for hypertrophic obstructive cardiomyopathy.
Q4: How does alcohol septal ablation differ from septal myectomy?
Alcohol septal ablation is a less invasive alternative to septal myectomy for hypertrophic cardiomyopathy patients unsuited for open-heart surgery. It involves injecting alcohol into a coronary artery to induce controlled infarction and septal thinning. However, it may have higher recurrence rates compared to septal myectomy.
Q5: What surgical options treat dilated cardiomyopathy?
Dilated cardiomyopathy management includes mitral valve repair or replacement to address secondary mitral regurgitation. For end-stage heart failure, left ventricular assist device implantation serves as a bridge to transplantation or long-term therapy. Cardiac transplantation is recommended for patients unresponsive to other treatments.
Q6: How does an implantable cardioverter-defibrillator help cardiomyopathy patients?
An implantable cardioverter-defibrillator (ICD) monitors and corrects life-threatening arrhythmias in cardiomyopathy patients. It significantly reduces the risk of sudden cardiac death and improves overall survival. ICDs are particularly valuable for patients at high risk of dangerous heart rhythm disturbances and provide continuous cardiac protection.
Q7: What role does cardiac resynchronization therapy play in cardiomyopathy treatment?
Cardiac resynchronization therapy (CRT), also called biventricular pacing, benefits patients with dilated cardiomyopathy by coordinating heart contractions. This therapy increases ejection fraction and can reverse some structural changes in the myocardium. It improves cardiac function and reduces heart failure symptoms in appropriately selected patients.